<DOC>
	<DOCNO>NCT02219685</DOCNO>
	<brief_summary>The primary objective study evaluate effect sustain virologic response ( SVR ) cerebral metabolism determine magnetic resonance spectroscopy ( MRS ) neurocognition measure neurocognitive test . This study also evaluate antiviral efficacy , safety , tolerability ledipasvir/sofosbuvir ( LDV/SOF ) fixed-dose combination ( FDC ) 12 week treatment-naive treatment-experienced adult . During blinded treatment phase , participant randomize 2:1 receive LDV/SOF FDC placebo 12 week . After unblinding Posttreatment Week 4 visit , participant placebo group offer open-label treatment LDV/SOF FDC 12 week .</brief_summary>
	<brief_title>Ledipasvir/Sofosbuvir Fixed-Dose Combination Cerebral Metabolism Neurocognition Treatment-Naive Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Chronic HCV infection ( â‰¥ 6 month ) document prior medical history liver biopsy Chronic genotype 1 HCV infection Screening laboratory value within define threshold Use protocolspecified method ( ) contraception female childbearing potential sexually active male Clinicallysignificant illness ( HCV ) major medical disorder may interfere treatment , assessment , compliance protocol . Current prior history follow : Hepatic decompensation Solid organ transplantation Significant pulmonary cardiac disease Chronic liver disease nonHCV etiology Hepatocellular carcinoma ( HCC ) Infection hepatitis B virus ( HBV ) Infection human immunodeficiency virus ( HIV ) History recent epilepsy ( within 2 year screen ) cerebral vascular accident ( CVA ) Structural brain damage Presence cirrhosis Contraindication MRI Pregnant nursing female Prior treatment NS5A directlyacting antiviral agent . Any interferon ( IFN ) contain regimen within 8 week Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>